Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Current Leases (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Current Leases for 3 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 2371.31% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, up 2371.31% year-over-year, with the annual reading at $3.0 million for FY2025, 2371.31% up from the prior year.
  • Current Leases for Q4 2025 was $3.0 million at Artiva Biotherapeutics, up from $75000.0 in the prior quarter.
  • The five-year high for Current Leases was $3.7 million in Q2 2024, with the low at $75000.0 in Q3 2025.
  • Average Current Leases over 3 years is $1.8 million, with a median of $1.6 million recorded in 2025.
  • Peak annual rise in Current Leases hit 2371.31% in 2025, while the deepest fall reached 97.92% in 2025.
  • Over 3 years, Current Leases stood at $3.6 million in 2023, then plummeted by 96.61% to $122000.0 in 2024, then skyrocketed by 2371.31% to $3.0 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $3.0 million, $75000.0, and $106000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.